北大医药: 第十一届董事会第十三次会议决议公告

Meeting Overview - The 13th meeting of the 11th Board of Directors of the company was held on August 20, 2025, in a hybrid format [1] - All 8 directors attended the meeting, with some participating via communication methods [1] - The meeting complied with relevant regulations, including the Company Law of the People's Republic of China [1] Financial Summary - The Board reviewed the company's actual operating performance for the first half of 2025 and prepared the half-year report and summary [1] - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 0.30 yuan per 10 shares, totaling 17,879,622.75 yuan [2] Capital Reduction and Liquidation - The company received a request from its associate, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., to reduce its registered capital from 300 million yuan to 100 million yuan due to severe operational difficulties [2] - The company plans to cooperate with the associate's capital reduction and subsequent liquidation process to optimize its investment layout and mitigate operational risks [2] Governance Structure Adjustment - The company proposed to adjust its governance structure by abolishing the supervisory board, transferring its powers to the audit committee of the board [3] - The relevant rules and regulations regarding the supervisory board will be abolished, and amendments to the company's articles of association will be made accordingly [3] Next Steps - The profit distribution plan and governance structure adjustments are subject to approval at the company's shareholders' meeting [4]